1,710 Shares in Aerie Pharmaceuticals Inc (AERI) Purchased by Girard Partners LTD.

Girard Partners LTD. purchased a new stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,710 shares of the company’s stock, valued at approximately $105,000.

Other institutional investors have also added to or reduced their stakes in the company. Fox Run Management L.L.C. purchased a new stake in Aerie Pharmaceuticals in the third quarter valued at about $201,000. First Republic Investment Management Inc. purchased a new stake in Aerie Pharmaceuticals in the second quarter valued at about $276,000. Public Employees Retirement Association of Colorado raised its stake in Aerie Pharmaceuticals by 48.6% in the third quarter. Public Employees Retirement Association of Colorado now owns 4,370 shares of the company’s stock valued at $269,000 after buying an additional 1,430 shares during the last quarter. GW Henssler & Associates Ltd. purchased a new stake in Aerie Pharmaceuticals in the third quarter valued at about $334,000. Finally, Amalgamated Bank raised its stake in Aerie Pharmaceuticals by 20.0% in the second quarter. Amalgamated Bank now owns 5,441 shares of the company’s stock valued at $368,000 after buying an additional 906 shares during the last quarter.

A number of research analysts have recently weighed in on the company. BidaskClub lowered Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 23rd. ValuEngine raised Aerie Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 14th. HC Wainwright set a $78.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $86.00 price objective on shares of Aerie Pharmaceuticals in a report on Tuesday, October 2nd. Finally, Canaccord Genuity reissued a “buy” rating and issued a $86.00 price objective on shares of Aerie Pharmaceuticals in a report on Friday, August 10th. Two research analysts have rated the stock with a sell rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $79.25.

In related news, Director Gerald D. Cagle bought 2,000 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The shares were purchased at an average cost of $41.75 per share, with a total value of $83,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Casey C. Kopczynski sold 11,000 shares of the firm’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $53.87, for a total value of $592,570.00. Following the sale, the insider now directly owns 139,768 shares in the company, valued at $7,529,302.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 324,117 shares of company stock worth $19,459,226. 10.53% of the stock is owned by corporate insiders.

Shares of AERI stock opened at $43.31 on Friday. The stock has a market capitalization of $1.97 billion, a PE ratio of -12.85 and a beta of 0.99. Aerie Pharmaceuticals Inc has a fifty-two week low of $40.47 and a fifty-two week high of $74.75.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Tuesday, November 6th. The company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.40). The firm had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.63 million. Sell-side analysts anticipate that Aerie Pharmaceuticals Inc will post -5.48 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was first published by WKRB News and is the property of of WKRB News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.wkrb13.com/2018/11/23/1710-shares-in-aerie-pharmaceuticals-inc-aeri-purchased-by-girard-partners-ltd.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

See Also: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply